1.05
-0.005(-0.48%)
Currency In USD
| Previous Close | 1.05 |
| Open | 1.02 |
| Day High | 1.05 |
| Day Low | 1.02 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.7 |
| Volume | 169,088 |
| Average Volume | 336,965 |
| Market Cap | 38.3M |
| PE | -2.9 |
| EPS | -0.36 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.1 |
| Change | -0.01 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $143.94 as of January 14, 2026 at a share price of $1.045. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $264.56 as of January 14, 2026 at a share price of $1.045.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a PK Profile that May Improve Clinical Efficacy and
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
GlobeNewswire Inc.
Dec 11, 2025 1:30 PM GMT
The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic DataMOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE N
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared dr